Post-Hoc Analyses Support Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Uncontrolled Eosinophilic Asthma and Prior Exacerbations. J of Skin [Internet]. 2025 Jan. 13 [cited 2026 Apr. 19];9(1):s524. Available from: https://skin.dermsquared.com/skin/article/view/3148